Consun Pharmaceutical Group (HKG:1681) reported a 16.1% increase in profit attributable to equity shareholders for 2024 to 910.5 million yuan from 784.5 million yuan a year earlier, according to a Wednesday filing with the Hong Kong bourse.
Earnings per share were 1.09 yuan, an 11.2% increase from 0.98 yuan the previous year.
Revenue increased by 14.6% to 2.97 billion yuan from 2.59 billion yuan in the prior year.
The board recommended a final dividend of HK$0.30 per share.